KeyBanc analyst Paul Knight lowered the firm’s price target on West Pharmaceutical to $315 from $350 and keeps an Overweight rating on the shares. Knight sees multiple indicators providing high visibility for the firm’s FY23 quarters and FY25 annual estimates, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on WST: